ACE-CL-001 trial showed an overall response rate of 97% with a sustained safety profile for previously untreated patients after more…
27 scientific presentations, including long-term data from Calquence in mantle cell lymphoma and updated early-phase trial results in chronic lymphocytic…
CAMBRIDGE, 07-Aug-2017 — /EuropaWire/ — AstraZeneca and its haematology research and development centre of excellence, Acerta Pharma, today announced that the…